retatrutide
Sponsor ELI Lilly & CO · listed as LLY
retatrutide is a drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Oct 2026 (month precision, medium confidence), tied to trial NCT06297603. That trial is in Phase 3 and currently active not recruiting, studying Type 2 Diabetes. It appears across 9 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for retatrutide
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-10-31 | READOUT | medium | NCT06297603 |
| 2026-11-30 | READOUT | medium | NCT06662383 |
| 2027-07-31 | READOUT | medium | NCT07232719 |
| 2027-09-30 | READOUT | medium | NCT07035093 |
Trials for retatrutide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06260722 | Phase 3 | Active, not recruiting | 2026-08-27 | Experimental | Eli Lilly and Company | Diabetes Mellitus, Type 2 |
| NCT06297603 catalyst | Phase 3 | Active, not recruiting | 2026-10 | Experimental | Eli Lilly and Company | Type 2 Diabetes |
| NCT06662383 catalyst | Phase 3 | Active, not recruiting | 2026-11 | Experimental | Eli Lilly and Company | Obesity |
| NCT07232719 catalyst | Phase 3 | Active, not recruiting | 2027-07 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| NCT07035093 catalyst | Phase 3 | Active, not recruiting | 2027-09 | Experimental | Eli Lilly and Company | Obesity; Overweight; Chronic Low Back Pain (CLBP) |
| NCT06859268 | Phase 3 | Active, not recruiting | 2028-04 | Experimental | Eli Lilly and Company | Obesity |
| NCT07357415 | Phase 3 | Active, not recruiting | 2028-10 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| NCT06383390 | Phase 3 | Active, not recruiting | 2029-02 | Experimental | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD) |
| NCT07165028 | Phase 3 | Recruiting | 2030-08 | Experimental | Eli Lilly and Company | Metabolic Dysfunction-Associated Steatotic Liver Disease |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More LLY catalysts